The anticollagenolytic potential of lymecycline in the long-term treatment of reactive arthritis.
OBJECTIVE
We sought to determine the antiinflammatory properties of lymecycline in the long-term treatment of reactive arthritis (ReA).


METHODS
Quantitative assay of collagenase activity by densitometry after sodium dodecyl sulfate-polyacrylamide gel electrophoresis.


RESULTS
Therapeutic levels of lymecycline do not directly inhibit the activity of human neutrophil interstitial collagenase, but can prevent the oxidative activation of latent human neutrophil collagenase.


CONCLUSIONS
This non-antimicrobial, anticollagenolytic property of lymecycline may contribute to its therapeutic efficacy in the treatment of patients with ReA.
Lauhio
A
A
Department of Medical Chemistry, University of Helsinki, Finland.
Sorsa
T
T
Lindy
O
O
Suomalainen
K
K
Saari
H
H
Golub
L M
LM
Konttinen
Y T
YT
D016918:Arthritis, Reactive / Q000188:drug therapy* / Q000201:enzymology; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008194:Lymecycline / Q000627:therapeutic use*; D003012:Microbial Collagenase / Q000187:drug effects* / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000201:enzymology; D000091402:Prohibitins
C000717331:PHB2 protein, human; D000091402:Prohibitins; D008194:Lymecycline; D003012:Microbial Collagenase